Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Qu Biologics opens Crohn’s disease clinical trial to US participants
Qu Biologics co-founder and CEO Dr Hal Gunn noted significant patient interest from the US in its Crohn’s disease clinical trial prompted us to open the trial to
Qu Biologics co-founder and CEO Dr Hal Gunn noted significant patient interest from the US in its Crohn’s disease clinical trial prompted us to open the trial to
Crohn’s disease is a chronic condition for which there is currently no satisfactory cure able to increase the quality of life for people who have Crohn’s disease. DBV
The acquisition is part of Medifirst Solutions plan to increase its internal technology infrastructure and add technical and digital services and expertise to its internal business operations. Medifirst
Forest has notified the US Food and Drug Administration of this decision. The oral solution of NAMENDA and once-daily NAMENDA XR (memantine HCl) extended-release capsules will continue to
The technology is being announced during the Advances in Genome Biology & Technology (AGBT) conference, which is recognized throughout the sequencing community as a cornerstone for the discussion
The 10 lots were manufactured by Agila Specialties Polska in Warsaw, Poland. All of the products bear a Pfizer label. Agila Specialties initiated the recall on 13 February
The launch will feature three products: Rabecure Pack 400 and Rabecure Pack 800, which package together individual blister sheets each containing a daily triple formulation dose of Pariet,
This synovial analysis, suggested by the FDA, tests the change in expression of signaling and structural proteins that arise from the treatment of the knee with either Ampion
The results of Study 801 from the Phase III clinical study demonstrate that extended-release hydrocodone was well tolerated and effective for the treatment of moderate-to-severe chronic low back
Bayer is licensing an early-stage drug discovery program directed against an epigenetic drug target. Inhibiting epigenetic targets is widely recognized as a promising emerging therapeutic option for cancer